Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Carcinoma, Non-Small-Cell Lung 119Squamous Cell Carcinoma of Head and Neck 60Melanoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 46Lung Neoplasms 45Triple Negative Breast Neoplasms 44Neoplasm Metastasis 42Breast Neoplasms 40Neoplasms 36Colorectal Neoplasms 31Head and Neck Neoplasms 27Endometrial Neoplasms 26Carcinoma, Renal Cell 26Ovarian Neoplasms 23Carcinoma, Transitional Cell 22Urinary Bladder Neoplasms 20Stomach Neoplasms 15Carcinoma 14Pancreatic Neoplasms 13Uterine Cervical Neoplasms 12Recurrence 12Esophageal Neoplasms 12Sarcoma 11Hodgkin Disease 11Brain Neoplasms 11Carcinoma, Squamous Cell 10Cholangiocarcinoma 9Carcinoma, Hepatocellular 9Skin Neoplasms 8Esophageal Squamous Cell Carcinoma 8

Interventions

pembrolizumab 4atezolizumab 3Cetuximab 3olaparib 2Trastuzumab 2Docetaxel 2zimberelimab 1tocilizumab 1spartalizumab 1ribociclib 1pralsetinib 1pertuzumab 1pegylated granulocyte colony-stimulating factor 1ipatasertib 1inavolisib 1fludarabine phosphate 1fludarabine 1entrectinib 1encorafenib 1cemiplimab 1binimetinib 1anlotinib 1amivantamab 1alectinib 1adagrasib 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Solid Tumors × pembrolizumab × 90 days × Clear all
NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Mirati Therapeutics Inc.

Phase 2 Recruiting
170 enrolled
Other solid neoplasm

Solid Tumors

NCT04123366 2026-04-22

MK-7339-007

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
300 enrolled
Other solid neoplasm

Solid Tumors

NCT03917381 2026-04-06

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Genmab

Phase 1/2 Active not recruiting
429 enrolled
Other solid neoplasm

Solid Tumors

NCT05101070 2026-03-18

aCCeleR8-001

Shionogi Inc.

Phase 1/2 Recruiting
282 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡